JAK1 and Alzheimer disease: In a post hoc analysis of the phase 3 trial BREEZE‐AD7, patients with itch‐dominant AD treated with the JAK1/2 inhibitor baricitinib, had significantly greater improvements in itch and disease severity versus placebo at Week 16.28